Introduction {#Sec1}
============

Disease comorbidity reflects the shared molecular mechanisms or environmental factors between diseases, which would be important for improving the knowledge and management of diseases in real-world clinical settings \[[@CR1]--[@CR3]\]. It has become a major problem in treatment \[[@CR4], [@CR5]\], because patients with comorbidity diseases have a higher probability of hospitalization and mortality \[[@CR6], [@CR7]\]. Furthermore, treating patients with multiple diseases is complicate and time - consuming, as it requires consideration of longer hospital stays and more expert consultations \[[@CR8], [@CR9]\]. For example, when a patient suffers from multiple diseases, the treating is particularly complicate \[[@CR10]\] because it involves uncertainty in diagnosis and treatment. If the patient takes multiple drugs at the same time, and the popular therapies with multiple drugs might cause serious side effects due to their interactions \[[@CR11], [@CR12]\].

Unfortunately, the patterns and the underlying mechanisms of disease comorbidity are far from fully elucidated \[[@CR13]\]. Therefore, recently, it has become a hot research topic on disease comorbidity both from clinical observations and molecular network mechanisms. Related studies explained the mechanism of the disease comorbidities of specific diseases. For example, studies have been conducted on the comorbidities of diabetes of adults \[[@CR14]\]. Also, some of the related studies focus on the relationship between diseases of genes, using Relative Risk and Φ-correlation to measure the correlation between two diseases \[[@CR15], [@CR16]\]. And there exists a study based on complex network including several diseases, for 613 nodes and 3277 edges in its network from 3,354,043 patients \[[@CR17]\]. However, in most cases, these studies are derived from the data in Europe and United States. In addition, it is interesting that machine learning methods are useful for predicting the patterns of biomedical entities, such as genes and proteins \[[@CR18]--[@CR20]\], when utilizing the meaningful features involved in biomedical data.

Here, we utilized a large-scale clinical data and conducted our research across the full range of diseases in China population. We built a large-scale disease comorbidity network (DCN) and obtained the topological properties and their relationships by complex network measurements. In addition, we validated the shared molecular mechanisms of the clinical disease comorbidities and investigated the possibility to predict the disease occurrence using the disease trajectories by machine learning methods. The results have implications for the disease comorbidity patterns and would be helpful to manage the chronic diseases conditions in clinical settings.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

Our main data were derived from the hospital discharge data held in the Data Center of the China Academy of Chinese Medical Sciences, which only includes two attributes, namely diagnostic codes and the encounter sequential identifiers of patients. This made our study strictly preserved the privacy of patients.

After removing of the records with missing diagnosis codes, we obtained 8,572,137 high-quality clinical records from 453 different hospitals in China. The diagnostic codes were recorded by ICD10 (the 10th revision of the International statistical classification of diseases \[[@CR21]\]) and we deal with them in the form of four-digit ICD10 codes for further analysis.

Disease-gene associations were derived from the MalaCards database \[[@CR22]\], which resulted in 64,245 disease-gene associations with 3193 diseases and 8616 genes. Meanwhile, we collected the pathway information (including 325 pathways and 7253 genes) from the KEGG Database \[[@CR23]\]. We further obtained the disease-pathway associations with 175,167 records by linking 3118 diseases and 324 pathways by combining the above two data sets.

Data analysis methods {#Sec4}
---------------------

### Correlation analysis {#Sec5}

We used Relative Risk (RR) and Φ-correlation \[[@CR15], [@CR16]\] to measure the correlations between disease pairs. When two diseases d~i~ and d~j~ co-occur more frequently than expected by chance, we would have RR~ij~ \> 1 and Φ~ij~ \> 0. The RR of observing a pair of d~i~ and d~j~ affecting the same patient is given by $$\documentclass[12pt]{minimal}
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                \begin{document}$$ {RR}_{ij}=\frac{C_{ij}N}{P_i{P}_j} $$\end{document}$$where C~ij~ is the number of patients affected by both diseases, N is the total number of patients in the population and P~i~ and P~j~ are the prevalence of diseases i and j. The Φ-correlation can be expressed as: $$\documentclass[12pt]{minimal}
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We constructed the DCN with those disease pairs with RR \> 1.0 and Φ \> 0.0 and the weights of disease pairs (links) were set as the co-occurrences of the corresponding diseases.

### Network analysis {#Sec6}

We constructed the DCN with nodes for the diseases of the comorbidity patterns extracted before. When two diseases co-occur on a patient, there's an edge between them. The weight of the edge is the co-occurrence times which represents the relationships between the two diseases. The weights of disease pairs of which the two diseases co-occur frequently will be large.

We used four topological measurements, namely, degree, betweenness centrality (BC), clustering coefficient (CC~1~) and closeness centrality (CC~2~), to evaluate the centrality of nodes in the network. Diseases with larger degree have more relationships with other diseases in the network \[[@CR23]\]. BC reflects the diversity of disease connection and the complexity of the disease. CC~1~ is used to measure the closeness of the neighbors to each other \[[@CR24]\]. That is, if disease d~1~ interacts with disease d~2~ and disease d~2~ interacts with disease d~3~, the possibility of the d~1~ interacting with d~3~ is also great. CC~2~ is an index of distribution of single-source shortest distance based on node, which vividly describes the importance of node's position in the network.

However, basic topological properties cannot fully capture the full characteristics of DCN. For example, the degree of a node only focuses on first-order connected nodes, but ignores the relationships beyond the neighboring nodes. The CC~1~ considers the closeness of adjacent nodes, but ignores the size of adjacent nodes. Therefore, we calculated the correlations between some topological measurements to identify the coupling and hierarchical patterns underlying the DCN.

Classification methods {#Sec7}
----------------------

It is well recognized that the dynamic networks of disease comorbidities would contribute to the outcome of patients \[[@CR15], [@CR16]\]. Here, we investigating the feasibility of predicting disease (e.g. hypertension and psychiatric diseases) occurrence based on the comorbid trajectories of patients using four machine learning algorithms, namely Logistic Regression (LR), SVM, Random Forest (RF) and Neural Network (NN). The main framework including the preprocessing of the data set is depicted in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1The framework to predict disease occurrence using the comorbid trajectories of patients

We curated patient cases that have at least two inpatient encounters. After that, for a particular disease which is diagnosed at a specific encounter for a given patient, we would consider the past histories of diseases as the predictor variables for that particular disease. In addition, we randomly selected a set of negative samples into the benchmark for classification methods. Now we described the main steps of disease prediction task as follows. We extracted totally 427,939 visits from the database based on the identifiers of a patient, which includes the whole comorbid trajectories of each patient;Transform the data records into datasets with features and classification labels. Diseases that the patient had in the previous visits were considered as the feature (excluding the target disease), and diseases that the patient had in the current visit were considered as classification label. To predict the occurrence of a specific target disease, we set to 1 if the target disease appears, and set to 0 for the other diseases.Train the classification models with the preprocessed data.Validate the classification model (using 10-fold cross validations) and obtain the significant associated disease risk factors for a given disease.Use the classification model to predict the disease risks.

Results {#Sec8}
=======

Basic properties of the disease comorbidity network {#Sec9}
---------------------------------------------------

We constructed the DCN with diseases whose co-occurrence \> 5, RR \> 1.0 and Φ-correlation \> 0.0. For these comorbid diseases filtered by the above two correlations, they actually obtained clinical meaningful relationships. For example, we found that the RR and Φ for hypertension and atherosclerotic heart disease is 2.53 and 0.2760, respectively. While the RR and Φ for hybrid asthma and atherosclerotic heart disease only got 1.3368 and 0.0002 respectively. The DCN has 5702 nodes and 258,535 edges with average degree 90.717(see Fig. [2](#Fig2){ref-type="fig"}a for degree distribution) and average edge weight 12,904.494(see Fig. [2](#Fig2){ref-type="fig"}b for weight distribution). In addition, the average path length is 2.528 and the average CC~1~ is 0.629 (see Fig. [2](#Fig2){ref-type="fig"}c for CC~1~ distribution), which indicated that DCN is a highly clustering network, with the neighbors of a disease closely connected. Fig. 2Basic properties of the network. **a** Distribution of degree. **b** Weight distribution of edges. **c** Distribution of CC~1~. **d** Distribution of BC. **e** Distribution of CC~2~. **f** The top 10 diseases with the highest degree, CC~2~ and BC, respectively

The power law distribution of degree and weight (Fig. [2](#Fig2){ref-type="fig"}a and Fig. [2](#Fig2){ref-type="fig"}b) showed that DCN is a scale-free network \[[@CR25]\], which means that some diseases (e.g. hypertension, atherosclerotic heart disease) have very high comorbidities in China population. We obtained the three disease lists, which are ranked as the top 10 diseases of degree, betweenness centrality and CC~1~ (Fig. [2](#Fig2){ref-type="fig"}f). It showed that hypertension, anaemia, other disorders of lung and other disorders of glycoprotein metabolism are the top 4 diseases included in all these rank lists.

Hierarchical modular structures of disease comorbidity network {#Sec10}
--------------------------------------------------------------

To identify the more elucidated patterns in the DCN, we calculated the correlations between several pairs of network topological measurements (Fig. [3](#Fig3){ref-type="fig"}a-f). We found that there exists negative correlation between degree and CC~1~ (Pearson correlation coefficient (PCC) = − 0.398, see Fig. [3](#Fig3){ref-type="fig"}a) in DCN, which indicated that DCN is a hierarchical modular network \[[@CR26]\]. Furthermore, consistently, we found that there exists negative correlation between CC~1~ and CC~2~ (PCC = -0.155, see Fig. [3](#Fig3){ref-type="fig"}b). These two results showed that in DCN, the neighbors of diseases located in the center of the network (easier to get to other nodes) have large diversity and diseases with less CC~2~ tend to occur simultaneously with diseases in the same module. Fig. 3The relationship between topological properties and the network structure. **a** Degree and CC~1~; **b** CC~2~ and CC~1~; **c** Degree and CC~2~; **d** BC and CC~2~; **e** Degree and BC; **f** CC~1~ and BC; **g** Modules in the network; **h** One specific disease comorbidity module in the network

Furthermore, the positive correlation between CC~2~ and degree (PCC = 0.596, see Fig. [3](#Fig3){ref-type="fig"}c) indicates that the data is reliable, because both the degree and close centrality reflect the centrality of a node.

The BC can reflect the diversity of disease connotation. There exists negative correlation between BC and CC~1~ (PCC = -0.181, see Fig. [3](#Fig3){ref-type="fig"}f), which shows that neighbors of the disease with large CC~1~ are not connected closely as a hub node. For example, as a hub node in DCN, hypertension has high BC and degree (BC = 0.093, degree = 1926), which reflects its diverse mechanisms and comorbid phenotypes. Also, the relationships between its neighbors are sparse (CC~1~ = 0.051), which indicate that there exist potential subtypes of hypertension disorder. For disorders of choroid (H31.8), its BC is 0. It has much fewer neighbors (degree = 12) but is more closely related to them than hypertension (CC~1~ = 1). That is to say, the number of the comorbidity diseases of the disease is few, but their relationship between their comorbid diseases is strong.

Disease comorbidity communities {#Sec11}
-------------------------------

To identify the disease comorbidity groups from the DCN, we applied BGLL community detection method \[[@CR27]\] to find the communities, which resulted in 10 communities with denser comorbidity links between the diseases other than random expectations (see Fig. [3](#Fig3){ref-type="fig"}g-h). There are both homogeneous and heterogeneous comorbidity diseases in the same communities. Meanwhile, there exist branching relationships between categories. For example, a specific disease comorbidity community (see Fig. [3](#Fig3){ref-type="fig"}h), includes 157(accounting for 74.8%) eye related diseases, which are caused by cataracts (H25-H26) and also contains 53(25.2%) diseases from other categories. Ocular comorbidity diseases are common in people with cataracts in real-world clinical settings \[[@CR28]\]. This would be insightful for the refinement of disease classification.

We found several common disease comorbidity patterns from 5702 diseases, such as diabetes and obesity \[[@CR29]\]. Hypertension occurs most frequently in the DCN. It has significant disease comorbidity patterns with arteriosclerosis heart disease (RR = 2.53, co-occurrence = 475,649), diabetes (RR = 2.56, co-occurrence = 383,436), cerebral infarction (RR = 2.70, co-occurrence = 367,144), hyperlipidemia (RR = 2.24, co-occurrence = 205,967) and heart failure (RR = 5.97, co-occurrence = 201,495). This is consistent with the popular prevalence of hypertension, which can lead to a variety of complications (e.g. cardiovascular disease \[[@CR30], [@CR31]\], diabetes \[[@CR32], [@CR33]\], renal failure \[[@CR34]\] and obesity \[[@CR35], [@CR36]\]) and cause damage to organs, such as the heart, brain and kidneys. It is well known that hypertension is a serious threat to the human health. The treatment of hypertension can reduce the occurrence of cardiovascular disease and alleviate its symptom. We also find other disease comorbidity patterns, such as Alzheimer disease and atherosclerotic heart disease, which can be supported by the evidence that cardiovascular and arterial disease is considered an important risk factor for Alzheimer's disease \[[@CR37]\]. It is similar for the findings of the relationship of diabetes and senile cataracts. Discovering these disease relationships is beneficial to the prevention of concurrent disease while discovering the primary disease.

Shared molecular mechanisms of disease comorbidities {#Sec12}
----------------------------------------------------

To validate the correlation between disease comorbidity and their underlying shared molecular mechanisms \[[@CR16]\] in our data, we calculated PCC between the number of shared genes and pathways and the strength of disease comorbidity (RR and Φ-correlation) in 258,543 disease pairs. We found that although the correlation is weak, there does exist significant positive correlation between comorbid diseases and their underlying molecular mechanisms (Table [1](#Tab1){ref-type="table"}), which indicates that if two diseases share genes or pathways, it will tend to have disease comorbidities. Table 1PCC between the disease comorbidity and shared molecular mechanismsShared genesShared pathwaysRR0.05312(*P* \< 2.2e-16)0.008511 (*P* = 0.01193)Φ-correlation0.23688(*P* \< 2.2e-16)0.037891 (*P* \< 2.2e-16)

In addition, we observed that the degree of disease comorbidity would be higher as their molecular correlation (shared genes and pathways) increased (see Fig. [4](#Fig4){ref-type="fig"}a and b). With the increase of molecular correlation, the degree of disease comorbidity gradually increases. Compared with the two diseases that do not share genes, the degree of diseases comorbidity of diseases sharing more than 20 genes has increased nearly five times. That is to say, the more genes the two diseases shared, the more likely there exists a disease comorbidity relationship. As the number of shared pathways increases, the comorbidity relationship becomes stronger. However, the impact is relatively weak, and there is a downward trend in the first two intervals. Therefore, we need to prevent the disease from happening while treating its comorbidity disease if they have shared genes or pathways. Fig. 4The shared molecular mechanisms of disease comorbidity. **a** The relationship between shared genes and intensity of disease comorbidity **b**. The relationship between shared pathways and intensity of disease comorbidity **c**. Disease comorbidity of Alzheimer's Disease and Arteriosclerotic Heart Disease

We further applied two commonly used similarity measures, namely Jaccard and Cosine measures, to identify the relationship between shared genes and pathways. We calculated the similarity and PCC between them*.* The positive correlation of them (see Table [2](#Tab2){ref-type="table"}) indicates that if the similarity of two diseases increases, the number of shared genes and pathways will increase as well. Table 2PCC between disease similarity and molecular mechanismsJaccardCosineShared genes0.1166 (*P* \< 2.2e-16)0.1312 (*P* \< 2.2e-16)Shared pathways0.0705 (*P* \< 2.2e-16)0.0826 (*P* \< 2.2e-16)

Furthermore, we found that several pairs of diseases not only have correlation at the gene level, but also show important disease comorbidity relationship, such as Alzheimer's disease and atherosclerotic heart disease (see Fig. [4](#Fig4){ref-type="fig"}c). There is a significant disease comorbidity relationship between them (RR = 2.585, Φ-correlation = 0.017), and they have shared genes (ACE, AOPE and NOS3). This shows that the existence of shared genes may lead to the co-occurrence of two diseases, which may be the direct reason of the disease comorbidity of them.

Disease prediction using the comorbid trajectories of patients {#Sec13}
--------------------------------------------------------------

To investigate the possibility of using disease comorbid trajectories to predict disease occurrence, we extracted 27,000 cases from our database and generated two benchmark data sets for two disease cases, namely hypertension and psychiatric diseases to demonstrate the feasibility (see Table [3](#Tab3){ref-type="table"}). It is noted that the coupled negative records were randomly selected from our database. We applied 4 machine learning methods (see Table [4](#Tab4){ref-type="table"} for detailed parameters) to predict the disease occurrence according to the previous diseases of a given patient. Table 3Positive and negative sample distribution in the data setData setPositiveNegativeTotalHypertension10,00010,00020,000Psychiatric diseases350035007000 Table 4Settings and parameters for classification methodsMethodsSettingLRusing L2 regularization normregularization intensity = 1SVMusing the linear kernel functionpenalty parameter of the error term = 10RFDecision tree = 180Bootstrap Sampleoob_score = trueFeature = Gini coefficientNNUsing multilayer feedforward neural networklearning rate = 0.001maximum number of iterations = 200two hidden layersrandomly optimizing the size of mini batches

Finally, we found that the prediction results of the 4 classification models on two disease datasets (see Table [5](#Tab5){ref-type="table"}) are acceptable. Among the two data sets, LR had the highest accuracy (0.6193 for hypertension and 0.6478 for psychiatric diseases) and NN had the lowest accuracy (0.5919 for hypertension and 0.6306 for psychiatric diseases), and RF has the highest recall (0.7534 for hypertension and 0.7358 for psychiatric diseases). Altogether, RF has the best F1-score in those four methods (0.6689 for hypertension and 0.6802 for psychiatric diseases). RF reaches the best result because it classified samples in a more interpretative way than NN and more complicated than LR. Also, with the limitation of simple networks and poor interpretability, NN may not be suitable for this task. Table 5The classification results of the four models on hypertension and psychiatric diseasesModelHypertensionPsychiatric diseasesPrecisionRecallF1-scorePrecisionRecallF1-scoreLR**0.6193 ±** 0.01400.6837 **±** 0.01830.6498 **±** 0.0127**0.6478 ±** 0.01970.6900 **±** 0.01940.6681 **±** 0.0178SVM0.6038 **±** 0.01680.7199 **±** 0.01520.6567 **±** 0.01380.6334 **±** 0.02070.7041 **±** 0.01920.6668 **±** 0.0179RF0.6034 **±** 0.0239**0.7534 ±** 0.0373**0.6689 ±** 0.00590.6386 **±** 0.0293**0.7358 ±** 0.0774**0.6802 ±** 0.0297NN0.5919 **±** 0.01510.6166 **±** 0.01180.6038 **±** 0.00840.6306 **±** 0.02250.6534 **±** 0.02750.6415 **±** 0.0219The highest values of the related measures are showed in bold values

In addition, we found the risk diseases that lead to hypertension and psychiatric diseases according to the coefficient in LR, SVM and RF (see Table [6](#Tab6){ref-type="table"}). For example, in the RF method, hypertensive heart disease with (congestive) heart failure (I11.0) is one of the risk factors of hypertension. If it appeared on a patient, it will be possible that hypertension appears. Previous study held the view that hypertension is the common reason of heart failure, and 50% patients with hypertension may have heart failure as comorbidities \[[@CR38]\]. Also, hypertension may cause effect to eyes and lead to a series of eye diseases (such as H35.0 and H52.3) \[[@CR39]\]. Similarly, as one of the risk factors of psychiatric diseases, palpitations (R00.2) appear frequently under the influence of the side effect of anti-psychotic drugs and effects of patients' own heart and disease \[[@CR40]\]. For SVM, Aortic (valve) stenosis with insufficiency (I35.2) is the risk factor. It appears with hypertension frequently and several studies counted the comorbidity pattern of them (morbidity = 20%\~ 68% \[[@CR41], [@CR42]\]). Pulmonary embolism with mention of acute cor pulmonale(I26.0), other specified inflammatory liver diseases(K75.8) and alcoholic liver disease, unspecified(K70.9) are risk factors. Due to the influence of anti-psychotic drugs, the burden on the liver will increase and the liver function will deteriorate. However, without the use of psychotropic drugs, the mood of patients will also cause liver failure. Therefore, patients with psychiatric diseases are more likely to suffer from lung disease, liver disease and heart disease complications than ordinary patients \[[@CR43]\]. Similarly, Atherosclerotic heart disease (I25.1) as the common cardiovascular diseases \[[@CR31], [@CR32]\] have the disease comorbidity relationships, which is similar to diabetes \[[@CR33], [@CR34]\]. In summary, although some evident cofounders, such as the missing recording of target diseases in the clinical settings, would involve target disease induced comorbidities conversely as the risk diseases, we obtained acceptable prediction results for the two demonstrating diseases. In addition, we found that several common diseases, such as, heart failure, cerebral infarction and lung disease, were filtered by the three classification methods as the main risk factors for the targeting disorders (see Table [6](#Tab6){ref-type="table"}). However, high rates of predicted risk diseases were different among the three methods, which is partially due to the mutual dependences between the risk diseases. For example, although the two risk diseases: E53.9(Vitamin B deficiency) and H35.0(a type of retinopathy and retinal disorders) predicted by SVM and LR respectively are different, they are two well recognized disorders with physio-pathological associations. Meanwhile, these predicted different features also means that it could be combined by more systematic frameworks to obtain more improved results in the future work. Table 6Important diseases for hypertension and psychiatric diseases in classification method0073LRSVMRFICD10DiseaseRegression coefficientICD10DiseaseFeature weightsICD10DiseaseImportanceHypertensionH35.0Background retinopathy and retinal vascular changes1.5174I35.2Aortic (valve) stenosis with insufficiency1.6055Z51.1Chemotherapy session for neoplasm0.0326A15.6Tuberculous pleurisy, confirmed bacteriologically and histologically1.4360A15.6Tuberculous pleurisy, confirmed bacteriologically and histologically1.5705I25.1Atherosclerotic heart disease0.0274I11.0Hypertensive heart disease with (congestive) heart failure1.3145E53.9Vitamin B deficiency, unspecified1.4400B18.1Chronic viral hepatitis B without delta-agent0.0188H52.3Anisometropia and aniseikonia1.2809E15.XNondiabetic hypoglycaemic coma1.4358I63.9Cerebral infarction, unspecified0.0184R10.1Pain localized to upper abdomen1.2530M89.9Disorder of bone, unspecified1.3565I50.9Heart failure, unspecified0.0184Psychiatric diseasesR00.2Palpitations1.6927I63.1Polydipsia1.5527Z51.1Chemotherapy session for neoplasm0.0323R62.8Other lack of expected normal physiological development1.4442I26.0Pulmonary embolism with mention of acute cor pulmonale1.5192C34.9Bronchus or lung, unspecified0.0250R79.8Other specified abnormal findings of blood chemistry1.3983K75.8Other specified inflammatory liver diseases1.5137I63.9Cerebral infarction, unspecified0.0236I63.1Cerebral infarction due to embolism of precerebral arteries1.3883K70.9Alcoholic liver disease, unspecified1.4400G30.9Alzheimer disease, unspecified0.0210E11.0Type 2 diabetes mellitus1.3871R79.8Other specified abnormal findings of blood chemistry1.3510C78.7Secondary malignant neoplasm of liver and intrahepatic bile duct0.0189

Discussion {#Sec14}
==========

Disease comorbidity holds significant medical insights and has its underlying molecular mechanisms \[[@CR15], [@CR16]\], which has been a hot research topic in both clinical and network medicine fields \[[@CR17]\]. However, most results were mainly derived from the analysis of the clinical data in Europe and United States. Due to the influence from environment factors, ethnicity and social factors to disease patterns, it is important to investigate the disease comorbidity patterns in large-scale populations in China \[[@CR14], [@CR44]\].

Our research is carried out across 5702 diseases in 22 categories and 8,572,137 patients with full range of the age groups. Therefore, the range of our study is more extensive in both data and scale than most previous studies in China population, which has great significance for the study of disease comorbidities. We focus on the DCN and analyzed the correlation of diseases in the network. Furthermore, we have investigated the relationships between the topological characteristics of DCN network and found biomedical meaningful patterns (i.e. the hierarchical structures of DCN). In terms of disease prediction, the prediction results are greatly influenced by the data, so the differences among countries, regions and populations in the data will also become obvious. It is significant for us to use China's disease comorbidity data to predict disease occurrence and detect the risk factors from comorbid disease conditions.

The major limitation of our research is that the recording of diseases in clinical data would prone to incomplete diagnoses. Because clinical practitioners would tend to record the diseases that they primarily treated rather than all the diseases of patients. This would particularly induce cofounders to our prediction results and make them vulnerable. Many factors (such as age, physical condition and treatment methods, etc.) will affect the occurrence and development of a disease, which have not been incorporated in our data set. Moreover, our prediction experiments are limited to the classical supervised learning methods, which mostly provides a feasible demonstration of the prediction of disease occurrence with comorbid trajectories. In the future, we will carry out more dedicated machine learning models with more systematic clinical features, such as deep learning, to obtain more powerful predictors, which might result in practical prediction applications using disease comorbidities.

Conclusion {#Sec15}
==========

We constructed a disease comorbidity network derived from millions of electronic medical records with diagnostic codes in China and found interesting topological patterns (e.g. high clustering and hierarchical modularity) for this network. Furthermore, we identified clinical meaningful disease comorbidity communities and revalidated the shared underlying molecular assumptions of disease comorbidity. Finally, by formulating the disease comorbid trajectories into a binary classification problem, we investigated the feasibility of predicting the disease occurrence using only the temporal relationships between disease phenotypes.
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